Groundbreaking DNA-based Solution Attempts to Tackle Soaring Emergency Room Visits Linked to Cannabis Consumption
BURBANK, Calif., June 5, 2023 /PRNewswire/ -- Endocanna Health ("Endocanna"), the industry leader in endocannabinoid system genomic testing, announces the issuance of a first-of-its-kind U.S. patent for its DNA test that brings to healthcare hyper-personalized cannabinoid therapies based on user genetics. The test helps consumers potentially avoid cannabis products that may cause negative health effects such as cannabis-induced psychosis and rapid heart rate.
- The test helps consumers potentially avoid cannabis products that may cause negative health effects such as cannabis-induced psychosis and rapid heart rate.
- Endocanna's patented technology reduces adverse effects
Emergency room visits resulting from cannabis consumption have skyrocketed where the plant is legal. - In California, cannabis-related emergency care visits among those aged 65 and older rose 1,804% from 2005 to 2019 .
- Such visits increased threefold in Colorado between 2012 and 2016 and increased fivefold in Ontario from 2003 to 2017.